TLR4 antagonists for endotoxemia and beyond

Current Opinion in Investigational Drugs

Volumn 6, Issue 5, 2005, Pages 496-502

  Rossignol, Daniel P ^a   Lynn, Melvyn ^a  

^a EISAI INC   (United States)

Author keywords

Endotoxemia; Endotoxin; Eritoran; Sepsis; Toll like receptor 4

Indexed keywords

ANTIINFECTIVE AGENT; B 464; B 975; E 5531; E 5564; ENDOTOXIN; ERITORAN; FIBRONECTIN; HEAT SHOCK PROTEIN; INTERLEUKIN 6; LIPID A DERIVATIVE; PLACEBO; PROTEIN INHIBITOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; ENDOTOXEMIA; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; IMMUNE RESPONSE; LIVER DISEASE; LUNG DISEASE; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; REPERFUSION INJURY; REVIEW; RHODOBACTER SPHAEROIDES; SEPSIS; SHOCK; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; ENDOTOXEMIA; HUMANS;

EID: 18144425200     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Sabroe I, Read RC, Whyte MK, Dockrell DH, Vogel SN, Dower SK: Toll-like receptors in health and disease: Complex questions remain. J Immunol (2003) 171(4):1630-1635.
2. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol (2001) 1(2):135-145.
3. Akira S, Takeda K, Kaisho T: Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol (2001) 2(8):675-680.
4. Seya T, Akazawa T, Uehori J, Matsumoto M, Azuma I, Toyoshima K: Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res (2003) 23(6A):4369-4376.
5. Christ WJ, Asano O, Robidoux ALC, Perez M, Wang Y, Dubuc GR, Gavin WE, Hawkins LD, McGuinness PD, Mullarkey MA, Lewis MD et al: E5531, a pure endotoxin antagonist of high potency. Science (1995) 268(5207):80-83.
6. Rossignol DP, Christ WJ, Hawkins LD, Kobayashi S, Kawata T, Lynn M, Yamatsu I, Kishi Y: Synthetic endotoxin antagonists. In: Endotoxin in Health and Disease. Brade H, Opal SM, Vogel SN, Morrison DC (Eds), Marcel Dekker Inc, New York, NY, USA (1999):699-717.
7. Hawkins LD, Christ WJ, Rossignol DP: Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem (2004) 4(11):1147-1171.
8. Krauss JH, Seydel U, Weckesser J, Mayer H: Structural analysis of the nontoxic lipid A of Rhodobacter capsulatus 37b4. Eur J Biochem (1989) 180(3):519-526.
9. Loppnow H, Libby P, Freudenberg M, Krauss JH, Weckesser J, Mayer H: Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect Immun (1990) 58(11):3743-3750.
10. Wasan KM, Strobel FW, Parrott SC, Lynn M, Christ WJ, Hawkins LD, Rossignol DP: Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels. Antimicrob Agents Chemother (1999) 43(10):2562-2564.
11. Qureshi N, Takayama K, Kurtz R: Diphosphoryl lipid A obtained from the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides is an endotoxin antagonist in mice. Infect Immun (1991) 59(1):441-444.
12. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, Przetak M, Chow J, Gusovsky F, Christ WJ, Rossignol DP: Inhibition of endotoxin response by E5564, a novel toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther (2003) 304(3):1093-1102.
13. Rossignol DP, Wasan KM, Choo E, Yau E, Wong N, Rose J, Moran J, Lynn M: Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous Intravenous infusion into healthy volunteers. Antimicrob Agents Chemother (2004) 48(9):3233-3240.
14. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF 3rd: The extra domain A of fibronectin activates toll-like receptor 4. J Biol Chem (2001) 276(13):10229-10233.
15. Zhang M, Shirota H, Chow J, Perron SI, Gusovsky F, Kobayashi S: LPS antagonist E5564 antagonises heat shock protein (HSP) 60- and 70-elicited innate immune response. J Endotoxin Research (2002) 8:201.
16. Kaneko K, Ueda R, Kawata T, Ishizaka S, Yoshimura T: LPS binding protein does not participate in the pharmacokinetics of E5564. J Endotoxin Res (2004) 10(3):185-194.
17. Akashi S, Saitoh S, Wakabayashi Y, Kikuchi T, Takamura N, Nagai Y, Kusumoto Y, Fukase K, Kusumoto S, Adachi Y, Kosugi A, Miyake K: Lipopolysaccharide interaction with cell surface toll-like receptor 4-MD-2: Higher affinity than that with MD-2 or CD14. J Exp Med (2003) 198(7):1035-1042.
18. Kobayashi S, Kawata T, Kimura A, Miyamoto K, Katayama K, Yamatsu I, Rossignol DP, Christ WJ, Kishi Y: Suppression of murine endotoxin response by E5531, a novel synthetic lipid A antagonist. Antimicrob Agents Chemother (1998) 42(11):2824-2829.
19. Michie HR: The value of animal models in the development of new drugs for the treatment of the sepsis syndrome. J Antimicrob Chemother (1998) 41(Suppl A):47-49.
20. Ridings P, Windsor AC, Rossignol DP, Christ WJ, Blocher C, Fisher BJ, Fowler AA, Sugerman HJ: A synthetic lipid A analogue, B464, provides significant protection against the cardiopulmonary derangements in porcine Gram-negative sepsis. J Endotoxin Res (2002) 2:121-130.
21. Bunnell E, Lynn M, Habet K, Neumann A, Perdomo CA, Friedhoff LT, Rogers SL, Parrillo JE: A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crit Care Med (2000) 28(8):2713-2720.
22. Kumar A, Bunnell E, Lynn M, Anel R, Habet K, Neumann A, Parrillo, JE: Experimental human endotoxemia is associated with depression of load-independent contractility indices: Prevention by the lipid A analogue E5531. Chest (2004) 126(3):860-867.
23. Wong YN, Rossignol D, Rose JR, Kao R, Carter A, Lynn M: Safety, pharmacokinetics and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J Clin Pharmacol (2003) 43(7):735-742.
24. Lynn M, Rossignol DP, Wheeler JL, Kao RJ, Perdomo CA, Noveck R, Vargas R, D'Angelo T, Gotzkowsky S, McMahon FG: Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis (2003) 187(4):631-639.
25. Lynn M, Wong YN, Wheeler JL, Kao RJ, Perdomo CA, Noveck R, Vargas R, D'Angelo T, Gotzkowsky S, McMahon FG, Wasan KM, Rossignol DP: Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia. J Pharmacol Exp Ther (2004) 308(1):175-181.
26. Rodrick ML, Moss NM, Grbic JT, Revhaug A, O'Dwyer ST, Michie HR, Gough DB, Dubravec D, Manson JM, Saporoschetz IB et al: Effects of in vivo endotoxin infusions on in vitro cellular immune responses in humans. J Clin Immunol (1992) 12(6):440-450.
27. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarelio CA, Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med (1988) 318(23):1481-1486.
28. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med (1993) 328(20):1471-1477.
29. Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, Parejo NA, Pribble JP, Lemke JH: Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis (1999) 180(5):1584-1589.
30. Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, Opal S, Abraham E, Brett SJ, Smith T, Mehta S et al: Diagnostic and prognostic implications of endotoxemia in critical illness: Results of the MEDIC study. J Infect Dis (2004) 190(3):527-534.
31. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med (2003) 31(4):1250-1256.
32. Soong CV, Halliday MI, Barclay GR, Hood JM, Rowlands BJ, Barros D'Sa AA: Intramucosal acidosis and systemic host responses in abdominal aortic aneurysm surgery. Crit Care Med (1997) 25(9):1472-1479.
33. Chieveley-Williams S, Hamilton-Davies C: The role of the gut in major surgical postoperative morbidity. Int Anesthesiol Clin (1999) 37(2):81-110.
34. Martinez-Pellus AE, Merino P, Bru M, Conejero R, Seller G, Munoz C, Fuentes T, Gonzalez G, Alvarez B: Can selective digestive decontamination avoid the endotoxemia and cytokine activation promoted by cardiopulmonary bypass? Crit Care Med (1993) 21(11):1684-1691.
35. Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Qureshi N, Sellevold OFM, Espevik T, Sundan A: Inflammatory response after open heart surgery: Release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation (2002) 105(6):685-690.
36. Bolger AP, Genth-Zotz S, Anker SD: Heat shock proteins and endotoxin combined as a trigger for inflammatory cytokine release during cardiopulmonary bypass: A possible third way? Circulation (2002) 106(11):e49-e50.
37. Ferrara JL, Cooke KR, Teshima T: The pathophysiology of acute graft-versus-host disease. Int J Hematol (2003) 78(3):181-187.
38. Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, Rossignol DP, Ferrara JL: LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest (2001) 107(12):1581-1589.
39. Nagy LE: Recent insights into the role of the innate immune system in the development of alcoholic liver disease. Exp Biol Med (2003) 228(8):882-890.
40. Oesterreicher C, Pfeffel F, Petermann D, Muller C: Increased in vitro production and serum levels of the soluble lipopolysaccharide receptor sCD14 in liver disease. J Hepatol (1995) 23(4):396-402.
41. Bradford BU, Wall CA, Ikejima K, Rossignol DP, Christ WJ, Thurman RG: The endotoxin antagonist B464 and antibiotics block the swift increase in alcohol metabolism. Hepatology (1995) 22:550.
42. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson U, Finberg RW: Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol (2000) 1(5):398-401.
43. Monick MM, Yarovinsky TO, Powers LS, Butler NS, Carter AB, Gudmundsson G, Hunninghake GW: Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem (2003) 278(52):53035-53044.
44. Gong JH, Sprenger H, Hinder F, Bender A, Schmidt A, Horch S, Nain M, Gemsa D: Influenza A virus infection of macrophages. Enhanced tumor necrosis factor-α (TNF-α) gene expression and lipopolysaccharide-triggered TNF-α release. J Immunol (1991) 147(10):3507-3513.
45. Schwartz DA, Thorne PS, Jagielo PJ, White GE, Bleuer SA, Frees KL: Endotoxin responsiveness and grain dust-induced inflammation in the lower respiratory tract. Am J Physiol (1994) 267(5 Pt 1):L609-L617.
46. Hollingsworth JW 2nd, Cook DN, Brass DM, Walker JK, Morgan DL, Foster WM, Schwartz DA: The role of toll-like receptor 4 in environmental airway injury in mice. Am J Respir Crit Care Med (2004) 170(2):126-132.
47. Cook DN, Pisetsky DS, Schwartz DA: Toll-like receptors in the pathogenesis of human disease. Nat Immunol (2004) 5(10):975-979.
48. Martin JL, Avkiran M, Quinlan RA, Cohen P, Marber MS: Antiischemic effects of SB203580 are mediated through the inhibition of p38α mitogen-activated protein kinase: Evidence from ectopic expression of an inhibition-resistant kinase. Circ Res (2001) 89(9):750-752.
49. Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ, Rothnie CL, Yada M, Pohlman TH, Verrier ED: Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg (2004) 128(2):170-179.
50. Rivest S: Molecular insights on the cerebral innate immune system. Brain Behav Immunol (2003) 17(1):13-19.
51. Woods JP, Frelinger JA, Warrack G, Cannon JG: Mouse genetic locus Lps influences susceptibility to Neisseria meningitidis infection. Infect Immun (1988) 56 (8):1950-1955.
52. Eisenstein TK, Deakins LW, Killer L, Saluk PH, Sultzer BM: Dissociation of innate susceptibility to Salmonella infection and endotoxin responsiveness in C3HeB/FeJ mice and other strains in the C3H lineage. Infect Immun (1982) 36(2):696-703.
53. Muller I, Freudenberg M, Kropf P, Kiderlen AF, Galanos C: Leishmania major infection in C57BL/10 mice differing at the Lps locus: A new non-healing phenotype. Med Microbiol Immunol (1997) 186(2-3):75-81.
54. Lorenz E, Schwartz DA, Martin PJ, Gooley T, Lin M-T, Chien JW, Hansen JA, Clark JG: Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2001) 7(7):384-387.
55. Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang K, Soudais C, Dupuis S, Feinberg J, Fieschi C, Elbim C et al: Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science (2003) 299(5615):2076-2079.
56. Eisai Co Ltd (McShane J, Arens T, Kaneko K, Watanabe T, Ashizawa K): Micelles. WO-00160382 (2001).